Northern Europe Keeps Up The Pressure On Biosimilar Infliximab Switching
This article was originally published in Scrip
Executive Summary
Northern European efforts to boost the use of biosimilar infliximab rather than Janssen's Remicade are gathering pace, with the Norwegian NOR-SWITCH study having been extended by 26 weeks to complete the switch from Remicade to Celltrion's biosimilar, Remsima, and a number of similar studies being conducted by both industry and non-commercial sponsors in the Netherlands.
You may also be interested in...
Remsima Stars In Orion Pharma’s First Half
Sales in Scandinavia of the biosimilar infliximab drove Orion’s specialty business in the first six months of 2016.
Remsima Stars In Orion Pharma’s First Half
Sales in Scandinavia of the biosimilar infliximab drove Orion’s specialty business in the first six months of 2016.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.